Adds allopurinol to sertraline for people with depression
Tests allopurinol added to sertraline in adults with major depressive disorder.
Plain-language title generated from the registry record
Registry title: Allopurinol in Depression
Key facts
- Where
- Tanta, EgyptSee the site
- Phase
- Phase 2/3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with major depressive disorder who have a moderate or higher depression score on the HAM-D scale.
- Age
- From 18 to 60 years old.
- Sex
- Men and women can join.
- Disease stage
- Major depressive disorder with a HAM-D score of at least 10, and a score of 2 or greater on item 1 (depressed mood).
Main reasons for not taking part
- Bipolar I or bipolar II disorder
- Eating disorders
- Pregnant women, or women not using medically accepted birth control
- Cardiovascular disorders
- Severe renal impairment
Read by machine on 13 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07574060, who can take part
Where in Egypt
- Tanta UnuversityTanta, EgyptContact: Mostafa M I Bahaa, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Tanta University
- Trial code
- NCT07574060
- Record updated
- 18 August 2026
- Original description
Major depressive disorder (MDD) is one of the most common psychiatric disorders with serious socioeconomic consequences on daily life and health care costs. Despite the advent of newer antidepressants that target monoamine pathways, nearly 50% of patients have no response to first-line antidepressant therapy. Thus, a combination of medications with different strategies at the beginning of treatment could provide further therapeutic benefits to MDD patients.Read full original descriptionShow less
Allopurinol Adjuvant Therapy in Patients With Major Depressive Disorder
Major depressive disorder (MDD) is one of the most common psychiatric disorders with serious socioeconomic consequences on daily life and health care costs. Despite the advent of newer antidepressants that target monoamine pathways, nearly 50% of patients have no response to first-line antidepressant therapy. Thus, a combination of medications with different strategies at the beginning of treatment could provide further therapeutic benefits to MDD patients.
Inclusion: Patients aged greater than 18 years old. Patients with a HAM-D score of at least 10 with item 1, depressed mood, scoring 2 or greater, are eligible.
Exclusion: Patients with bipolar I or bipolar II disorder Patients with eating disorders Pregnant women or women not using medically accepted means of birth control Cardiovascular disorders Severe renal impairment.